Triple Incretin Agonism as a Metabolic Terrain Modulator: Translational Evidence and Mechanistic Constraints for Retatrutide in Solid Tumors
Abstract
1.Introduction: The Metabolic Terrain
Tumor progression depends not only on cell-intrinsic mutations but on a permissive host environment. Three features of the obese, insulin-resistant state are mechanistically linked to malignancy:
1. Hyperinsulinemia and the IGF-1 axis. Elevated insulin acts as a mitogen, driving IGF-1 signaling and the PI3K/AKT/mTOR cascade that suppresses apoptosis and promotes proliferation.[10]Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.Nature · DOI: 10.1038/s41586-018-0343-4
2. Glycolytic substrate excess (the Warburg effect). Many solid tumors upregulate glucose uptake to fuel biomass synthesis; substrate abundance in the hyperglycemic state supports this program.[11]Understanding the Warburg effect: the metabolic requirements of cell proliferation.Science · DOI: 10.1126/science.1160809
3. Obesity-associated immune dysregulation. Adipose-derived inflammatory signaling and expansion of immunosuppressive myeloid populations impair anti-tumor immune surveillance.
If these features constitute a pro-tumor terrain, then pharmacologic correction of the terrain is a plausible, but unproven, lever on tumor biology. Retatrutide, by virtue of its potency and triple-receptor pharmacology, provides an unusually strong tool to test this idea. This review evaluates that hypothesis and, equally, the reasons for caution.
2.Emerging Clinical Signals: Preliminary ASCO 2026 Data
Evidentiary caveat (applies to all of Section 2). The following are retrospective, observational analyses presented as conference abstracts at ASCO 2026. They are not yet peer-reviewed, are subject to residual confounding (most importantly by weight loss and by indication), and cannot establish causality. They are hypothesis-generating signals, not evidence of effect.
Breast Cancer Incidence
In a single-center cohort of women undergoing breast imaging (analytic n = 94,827; median age 61), GLP-1 receptor agonist exposure was associated with lower breast cancer incidence: matched odds ratio 0.746 (95% CI 0.632–0.880), approximately 25% lower; the unmatched odds ratio was 0.630.[7]Association of GLP-1 agonists with breast cancer incidence in women.J Clin Oncol · Abstract 10506
Metastatic Progression Across Solid Tumors
Among 10,225 patients with stage I–III cancer initiating GLP-1RA therapy after diagnosis, propensity-matched 1:1 to DPP-4 inhibitor controls, progression to stage IV was significantly reduced in 4 of 7 tumor types.[6]Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors.J Clin Oncol · Abstract 3143
| Tumor Type | Cumulative Incidence (GLP-1RA) | Cumulative Incidence (DPP-4i) | HR (95% CI) |
|---|---|---|---|
| NSCLC | 10.0% | 22.3% | 0.50 (0.43–0.59) |
| Breast | 10.2% | 20.1% | 0.57 (0.46–0.71) |
| Colorectal | 13.4% | 22.2% | 0.69 (0.54–0.88) |
| HCC | 18.9% | 28.4% | 0.62 (0.44–0.89) |
| Prostate | — | — | 0.79 (p=0.09, NS) |
| Renal cell | — | — | 0.95 (p=0.76, NS) |
| Pancreatic | — | — | 0.69 (p=0.14, NS) |
Table 1. Stage IV progression HRs by tumor type (GLP-1RA vs DPP-4i, propensity-matched n=10,225). Bold = statistically significant. NS = not significant. Source: Orland et al., ASCO 2026 Abstract 3143 (conference abstract; not peer-reviewed).[6]
In TCGA data, higher tumor GLP-1R expression correlated with improved overall survival (HR 0.67; breast HR 0.55). The abstract reported no significant safety signals or increased adverse events in exposed patients.[6]
Endometrial Cancer Outcomes
In a global federated-network analysis of patients with endometrial cancer and comorbid obesity (6,352 per matched arm), GLP-1RA exposure was associated with lower overall mortality (HR 0.45, 95% CI 0.39–0.51) and reduced peritoneal (RD −2.16%), visceral (RD −3.76%, p=0.01), and nodal (RD −0.41%) metastases. Differences in myocardial infarction, stroke, ED visits, and pancreatitis were not significant.[8]Real-world outcomes comparing the use of GLP-1 receptor agonists in patients with endometrial cancer and comorbid obesity.J Clin Oncol · Abstract 5543
The consistency of direction across independent datasets is notable. The uniform confounding by weight loss is the reason these remain signals rather than conclusions.
3.Preclinical Evidence
Sections 3.1 and 3.2 derive from a single research program (Makowski laboratory). They should be read as one body of work at two doses, not as independent replication. Section 3.3 is a mechanistically distinct, independently conducted line of evidence.
3.1Therapeutic-Dose Retatrutide in Pancreatic and Lung Models
In diet-induced obese mice, retatrutide (30 nmol/kg every other day) reduced pancreatic (KPCY) tumor volume approximately 14-fold versus vehicle, compared with only ~3-fold for semaglutide and for a weight-matched caloric-restriction control; in a Lewis lung carcinoma model it produced a ~17-fold tumor-volume reduction with engraftment falling to 50% (4/8 vs 7/7).[1]Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression.npj Metab Health Dis · DOI: 10.1038/s44324-025-00054-5 Weight loss reached 38–41%.
Critically, anti-tumor protection persisted after drug withdrawal and weight regain: the tumor transcriptome reverted toward vehicle, yet progression remained blunted, suggesting effects not fully explained by concurrent weight loss. Immune profiling showed reduced monocytic and polymorphonuclear MDSCs, enrichment of MHC-II-high macrophages, and increased CD8⁺ PD-1 expression. The authors explicitly state that a weight-loss-mediated mechanism cannot be excluded.[1]
3.2Sub-Therapeutic, Weight-Stable Dosing and Anti-PD-1 Combination
In a companion study at a sub-therapeutic dose (1 nmol/kg), body weight remained stable while blood glucose fell, and pancreatic tumor volume was still reduced ~3-fold, comparable to but numerically below anti-PD-1 monotherapy (~5-fold). The combination of low-dose retatrutide with anti-PD-1 produced ~4-fold reduction, indicating no synergy.[2]Sub-therapeutic retatrutide and anti-PD-1 in pancreatic cancer.J Immunother Cancer · SITC 2025 Abstract 661
The weight-stable arm is the strongest single piece of evidence that metabolic correction, rather than cachexia, drives part of the effect. It is also preliminary (conference abstract) and from the same research program.
3.3Independent Mechanistic Line: TNBC
In obese triple-negative breast cancer models, retatrutide (5 mg/kg twice weekly) suppressed the hexosamine biosynthetic pathway, reducing O-GlcNAcylation of YAP at Thr83 and its EIF3H-mediated stabilization, thereby decreasing YAP-driven growth and chemoresistance. Effects were most pronounced in obese animals and enhanced chemotherapy efficacy.[3]Pharmacological dissection identifies retatrutide overcomes the therapeutic barrier of obese TNBC through suppressing the interplay between glycosylation and ubiquitylation of YAP.Adv Sci · DOI: 10.1002/advs.202407494
This is a distinct mechanism, cancer type, and laboratory, and therefore the most independent preclinical corroboration available. The authors note that retatrutide's multi-receptor metabolic effects may act in parallel with, or independently of, YAP — again raising the metabolic mediation question.
4.Human Pharmacology and Tolerability
No human oncologic dose of retatrutide exists. The human data below describe metabolic efficacy and tolerability in obesity and MASLD — the doses a future interception trial would most plausibly test.
Phase 2 — Obesity (n=338)
At 48 weeks, least-squares mean weight change was −8.7% (1 mg), −17.1% (4 mg), −22.8% (8 mg), and −24.2% (12 mg) versus −2.1% for placebo.[4]Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial.N Engl J Med · DOI: 10.1056/NEJMoa2301972 LDL-cholesterol reduced approximately 20% (possibly via glucagon effects on PCSK9), and 72% of participants with baseline prediabetes reverted to normoglycemia (vs 22% placebo).
| Dose | Weight Change (48 wk) | GI AEs (most common) | Discontinuation |
|---|---|---|---|
| Placebo | −2.1% | — | 0% |
| 1 mg | −8.7% | Dose-related | 6% |
| 4 mg | −17.1% | Dose-related | ~10% |
| 8 mg | −22.8% | Dose-related | ~14% |
| 12 mg | −24.2% | Dose-related | 16% |
Table 2. Phase 2 weight outcomes by dose. Source: Jastreboff et al., NEJM 2023.[4] Note: cutaneous hyperesthesia occurred in 7% retatrutide vs 1% placebo.
Phase 2a MASLD Substudy
Liver-fat reduction at 24 weeks was dose-dependent: −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), and −82.4% (12 mg).[5]Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.Nat Med · DOI: 10.1038/s41591-024-03018-2 Fasting triglycerides were reduced by more than 40% at 8–12 mg doses by 48 weeks.
Lipoprotein and Apolipoprotein Effects
A secondary analysis of the phase 2 obesity trial presented at ESC Congress reported dose-dependent reductions in atherogenic lipoproteins: non-HDL-cholesterol fell by up to 22.2% (24 wk) and 26.9% (48 wk); apolipoprotein B by up to 19.6% (24 wk) and 24.2% (48 wk).[12]Retatrutide significantly improves lipoprotein and apolipoprotein profiles in participants with obesity.Eur Heart J (ESC 2024 Congress Abstract) These figures are cited from a conference abstract and carry the corresponding evidentiary caveat.
Phase 3 Topline — TRIUMPH-1
Eli Lilly's TRIUMPH-1 program (NCT05929066) reported topline weight reductions and, notably, a discontinuation rate at the 4 mg dose (~4.1%) at or below placebo, suggesting a lower dose may offer a favorable tolerability-to-effect ratio.[9]TRIUMPH-1 phase 3 topline results for retatrutide.Press release (not peer-reviewed) These figures are from a press release and are not yet peer-reviewed.
5.Proposed Dual-Axis Mechanism
Axis A — Metabolic Substrate Restriction
By reducing hyperinsulinemia and hepatic steatosis and improving glycemic control, retatrutide may attenuate IGF-1/PI3K/AKT/mTOR signaling and limit glycolytic substrate availability, activating AMPK and restraining mTORC1-driven biomass expansion. GCGR agonism contributes by suppressing de novo lipogenesis and increasing hepatic fat oxidation.
Axis B — Immune Reprogramming
The preclinical immune phenotype is one of reprogramming, not global anti-inflammation: MDSC populations fall and antigen-presenting capacity rises, yet circulating IL-6 increased (up to ~4.6-fold in the lung model), and TNF-α and MCP-1 were unchanged.[1] IL-6 has context-dependent pro- and anti-tumor roles; the data do not support a simple "retatrutide lowers inflammation" narrative, and this mechanism should be characterized as immune-compositional change with an unresolved cytokine picture.
6.Limitations and Constraints
The following constraints apply uniformly to the evidence reviewed above and must not be minimized in clinical discussion:
1. Single-program preclinical base. Sections 3.1–3.2 are one laboratory's work; independent replication is needed before mechanistic claims harden.
2. Weight-loss confounding. Across every dataset, anti-tumor effects co-occur with weight loss. The weight-stable arm (§3.2) mitigates but does not eliminate this. Authors of the primary studies state the weight-mediated mechanism cannot be excluded.
3. No human oncologic dose. All human data are metabolic; the effective and safe oncologic dose, if any, is unknown.
4. Conference-abstract tier. Section 2's human signals are unadjusted-for-publication, non-peer-reviewed abstracts.
5. No checkpoint-inhibitor synergy. Low-dose retatrutide did not add to anti-PD-1 in the pancreatic model (§3.2); sequencing and combination strategy are unresolved.
6. Thyroid signal. A modest class-level thyroid-cancer signal is noted in the broader GLP-1 literature and must not be omitted from any clinical discussion.
7. Compound integrity. Gray-market research peptides risk endotoxin (LPS) and heavy-metal contamination. In any oncologic or preventive context, clinical-grade verification (HPLC, mass spectrometry) is mandatory. This caution is heightened, not lessened, by the lead author's commercial interest (see Declarations).
§6.6Ophthalmic Safety and Monitoring
Drafted for co-author review; to be verified and finalized by Dr. Catapang, who holds authorship accountability for this section.
Two ophthalmic safety signals associated with GLP-1 receptor agonists warrant explicit consideration before any oncologic or preventive use of retatrutide. Neither has been studied for retatrutide specifically, and neither appears in the ASCO oncology datasets in Section 2; both derive from the GLP-1 class and justify vigilance rather than exclusion.
Diabetic Retinopathy
In the SUSTAIN-6 cardiovascular outcomes trial, semaglutide was associated with a significantly higher rate of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring intravitreal therapy or photocoagulation): HR 1.76 (95% CI 1.11–2.78).[13]Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6).N Engl J Med · DOI: 10.1056/NEJMoa1607141 The leading explanation is early worsening of retinopathy following rapid glycemic improvement — a well-recognized phenomenon with intensive glucose lowering, rather than direct retinal toxicity. Patients with pre-existing retinopathy and long-standing hyperglycemia are at greatest risk.
Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
A single-institution matched cohort reported markedly elevated NAION risk with semaglutide (HR 4.28 in type 2 diabetes; HR 7.64 in overweight/obesity).[14]Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide.JAMA Ophthalmol · DOI: 10.1001/jamaophthalmol.2024.2296 A subsequent, much larger multi-database replication found a more modest association (incidence rate ratio 1.32; 95% CI 1.14–1.54).[15]Semaglutide and nonarteritic anterior ischemic optic neuropathy.JAMA Ophthalmol · DOI: 10.1001/jamaophthalmol.2024.6555 The true effect size is unsettled, but a real if small absolute risk increase cannot be excluded. Proposed mechanisms involve hemodynamic compromise of a structurally crowded optic disc ("disc at risk").
Proposed monitoring framework (for any future trial or supervised use): (1) Baseline dilated fundus examination documenting retinopathy stage and optic-disc morphology; (2) for moderate or worse pre-existing retinopathy, ophthalmologic review before starting and a slower glucose-lowering trajectory; (3) scheduled surveillance at 3–6 months during the period of most rapid metabolic change, then annually; (4) immediate ophthalmologic referral for any acute visual change, with NAION explicitly considered; (5) predefined stopping criteria for progressive sight-threatening retinopathy or incident NAION.
7.Testable Predictions and Proposed Study Designs
If the terrain hypothesis is correct, the following should hold:
| Prediction | What it tests |
|---|---|
| P1. In a prospective interception trial in metabolically high-risk patients, GLP-1/triple-agonist exposure will reduce incident obesity-associated cancers versus standard care. | Direct cancer-risk reduction hypothesis |
| P2. Anti-tumor benefit will persist when weight loss is held constant (weight-matched comparator arms), directly testing the weight-confounding objection. | Decoupling weight loss from mechanism |
| P3. Benefit will track with tumor GLP-1R expression and degree of metabolic correction, not with weight loss alone. | Biomarker-stratified terrain hypothesis |
| P4. Sequencing matters: metabolic priming before immunotherapy will outperform concurrent administration (given the absence of concurrent synergy in §3.2). | Combination sequencing strategy |
Proposed designs: (a) weight-matched preclinical replication across independent laboratories; (b) a biomarker-stratified window-of-opportunity trial measuring tumor immune composition pre/post exposure; (c) a registry-embedded interception study in metabolically high-risk cohorts.
8.Conclusion
Metabolic and immune regulation of the tumor terrain are linked, and retatrutide is an unusually potent tool to probe that link. The preclinical, mechanistic, and epidemiologic signals point in a consistent direction, but every line of evidence carries a weight-loss confound, the preclinical base is narrow, and no human oncologic dose exists.
The defensible conclusion is not that retatrutide is a "metabolic shield" to be deployed, but that it is a strong candidate for rigorous prospective oncology investigation. The next step is hypothesis-testing, not clinical adoption.
Declarations
References
-
1
Marathe SJ, Grey EW, Bohm MS, et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. npj Metab Health Dis. 2025;3:10.
DOI: 10.1038/s44324-025-00054-5 ↗ -
2
Marathe SJ, Bohm MS, Powell Z, et al. [Sub-therapeutic retatrutide and anti-PD-1 in pancreatic cancer.] SITC 2025. J Immunother Cancer. 2025;13(Suppl 2):A752, Abstract 661.
DOI: 10.1136/jitc-2025-SITC2025.0661 ↗ -
3
Cui X, Zhu Y, Zeng L, et al; Wan Y. Pharmacological dissection identifies retatrutide overcomes the therapeutic barrier of obese TNBC through suppressing the interplay between glycosylation and ubiquitylation of YAP. Adv Sci. 2025;12(11):e2407494.
DOI: 10.1002/advs.202407494 ↗ -
4
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514–526.
DOI: 10.1056/NEJMoa2301972 ↗ -
5
Sanyal AJ, Kaplan LM, Frías JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037–2048.
DOI: 10.1038/s41591-024-03018-2 ↗ -
6
Orland MD, Mandala A, Unlu S, et al. Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. J Clin Oncol. 2026;44(16_suppl):Abstract 3143.
DOI: 10.1200/JCO.2026.44.16_suppl.3143 ↗
Conference abstract · ASCO 2026 · Not peer-reviewed -
7
McDonald ES, Gillis L, Gabriel P, et al. Association of GLP-1 agonists with breast cancer incidence in women. J Clin Oncol. 2026;44(16_suppl):Abstract 10506.
DOI: 10.1200/JCO.2026.44.16_suppl.10506 ↗
Conference abstract · ASCO 2026 · Not peer-reviewed -
8
Arya Y, Syal A, Jones C, et al. Real-world outcomes comparing the use of GLP-1 receptor agonists in patients with endometrial cancer and comorbid obesity. J Clin Oncol. 2026;44(16_suppl):Abstract 5543.
DOI: 10.1200/JCO.2026.44.16_suppl.5543 ↗
Conference abstract · ASCO 2026 · Not peer-reviewed -
9
Eli Lilly and Company. TRIUMPH-1 phase 3 topline results for retatrutide (NCT05929066). Press release, May 2026. Replace with peer-reviewed publication when available.
-
10
Hopkins BD, Pauli C, Du X, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature. 2018;560(7719):499–503.
DOI: 10.1038/s41586-018-0343-4 ↗ -
11
Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.
DOI: 10.1126/science.1160809 ↗ -
12
[Retatrutide investigators]. Triple-hormone receptor agonist retatrutide significantly improves lipoprotein and apolipoprotein profiles in participants with obesity or overweight. Eur Heart J. 2024;45(Suppl 1), ESC Congress 2024 abstract.
Secondary analysis of NCT04881760. Confirm full citation before journal submission. -
13
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844.
DOI: 10.1056/NEJMoa1607141 ↗ -
14
Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732–739.
DOI: 10.1001/jamaophthalmol.2024.2296 ↗ -
15
Cai CX, Hribar M, Baxter S, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025;143(4):304–314.
DOI: 10.1001/jamaophthalmol.2024.6555 ↗